PubMed Health⌕ Search

PubMed · 11740442

[Buruli ulcer. A case report].

Abstract

The authors report a case of skin infection, Buruli ulcer, which is widespread in several parts of Africa: Ghana, Uganda, Ivory Coast, Senegal and most central African countries. This infection is caused by Mycobacterium ulcerans which belongs to the non-tubercular species Mycobacterium. It resembles Mycobacterium tuberculosis in colour and morphology, but differs in its speed of growth, its nutritional requirements, its capacity to produce pigments with enzymatic activities, its heat sensitivity and its resistance to anti-tubercular agents. Mycobacterium infection follows the percutaneous inoculation of the latter and appears as a painless, erythematous nodule that develops central necrosis and ulceration. Initially, the lesion appears as skin necrosis leading to the ulceration of the dermis and epidermis. The histological lesion shows a coagulative necrosis of the deep dermis and epidermis with destruction of the nerves and blood vessels; interstitial edema is also present. Healing is accompanied by a granulomatous response and the affected area is generally covered by a depressed scar. The authors initially treated the case in question using a conservative approach. A gel (Intrasite Gel) was used whose properties allowed the destruction of necrotic tissue present on the ulcer bed and the stimulation of granulation tissue formation. The layer of gel was in turn covered with a triple layer of polyurethane which enabled the humidity of the lesion to be maintained constant, thus promoting healing and acting as a barrier against external germs. This treatment enabled the skin lesion to be completely sterilised in about 30 days using new dressings every 3 days. Surgical treatment then led to complete healing after a further 20 days.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

A Merone, G Saggiomo, G Severino, D Capone, G De Vincentiis. 2001. [Buruli ulcer. A case report].. https://pubmed.ncbi.nlm.nih.gov/11740442/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Prevalence and risk factors for persistent faecal carriage of extended spectrum beta-lactamase producing Escherichia coli in a paediatric community population.

OBJECTIVE: To investigate clinical and microbiological factors associated with persistent faecal carriage of extended spectrum beta-lactamase (ESBL) producing Escherichia coli in infants. METHODS: Between 2010 and 2022, children aged 3 months to 2 years old were sampled in a community setting in France, at two visits, V1 and V2, 3-24 months apart, to screen for prolonged faecal carriage of ESBL-producing E. coli. Patient clinical information and whole genome sequence of each isolate were used for association studies. RESULTS: A total of 4641 children were sampled. 375 (8%) carried an ESBL-producing Enterobacterales, among which 142 of ESBL-producing E. coli carriers were once again sampled at V2 and included in this study. 21.8% (n = 31/142) and 18.4% (n = 16/99) carried the same ESBL-producing E. coli clone for at least 3 and 6 months, respectively. B2 phylogroup, and among which ST131 clones were associated with an increased risk of persistent carriage. Multivariate analysis identified virulence associated genes involved in adhesion (papC/papGII allele and a tia-like gene) and encoding toxin (senB) as major risk factors for persistence. A genome wide association study highlighted the potential role of the frz metabolic operon, known to be involved in enterocytes adhesion/internalisation. CONCLUSION: Main extraintestinal pathogenic E. coli genomic features (phylogenetic background, adhesion properties) are associated with ESBL-producing E. coli gut colonisation persistence in infants, which could potentially lead to an increased risk of febrile urinary tract infection in these patients.

Child↗

Extensive and differential platinum chemotherapy mutagenesis in livers of children.

Childhood cancer survivors often experience late adverse effects that may be linked to chemotherapy mutagenesis. We studied chemotherapy mutagenesis in normal pediatric tissues using duplex sequencing (NanoSeq) to enable the detection of mutations from single DNA molecules. We found that platinum chemotherapeutics increased the mutation burdens of normal pediatric tissues to levels seen in adults. In the liver, platinum agents imparted a tissue-specific mutational signature that was absent from other tissues. Gene-focused duplex sequencing revealed that chemotherapy mutagenesis generates a great diversity of nonsynonymous variants, some of which may have functional potential, such as leukemogenic variants in blood. Our findings demonstrate extensive chemotherapy mutagenesis in normal tissues of children, which may provide a plausible link between chemotherapy exposure and adverse effects in later life.

Child↗

Clinical and immunological characterization of a child with a homozygous TBK1 kinase-domain truncation.

TBK1 is a serine-tyrosine kinase protein that transmits signals from pattern recognition receptors to the NF-κB pathway leading to production of Type 1 Interferons. Mutations in this protein have been associated with arthritis, vasculitis, herpes simplex encephalitis and amyotrophic lateral sclerosis. In the current study, we characterized the functional consequences of a TBK1-variant bearing a truncation in exon 4 and 5 in a patient with poly arthritis resembling juvenile idiopathic arthritis and necrotizing encephalitis. The truncation was associated with reduced TBK1 protein abundance and altered phosphorylation. The variant was associated with increased basal/and or Poly-I: C induced IL-6, TNFα, IL-1β and IL-18 and type 1 Interferon ex vivo. Our findings expand the phenotypic spectrum of TBK1 loss-of-function variants and may provide insight into the management of immune dysregulation in affected patients.

Child↗